Latest Cylene Pharmaceuticals Inc. Stories

2011-06-06 08:00:00

SAN DIEGO, June 6, 2011 /PRNewswire/ -- Cylene Pharmaceuticals, Inc.

2010-12-06 07:00:00

SAN DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc.

2010-11-16 07:00:00

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany.

2010-09-24 07:00:00

SAN DIEGO, Sept. 24 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma.

2010-09-08 07:00:00

SAN DIEGO, Sept. 8 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

Word of the Day
  • Emitting flashes of light; glittering.
The word 'coruscant' comes from a Latin word meaning 'to flash' or 'to sparkle'.